Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Held On December 16,2023

1. To consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, American Depository Receipts/Global Depository Receipts/Foreign Currency Convertible Bonds, qualified institutions placement, debt issue, preferential issue or any other method, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and any other regulations and rules as applicable, as amended subject to such regulatory/ statutory approvals as may be required. 2. The Information required to be submitted pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023 is annexed herewith as Annexure I. The meeting commenced at 03:00 pm and concluded at 06:30 pm.
16-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

In compliance with Regulation 39 of SEBI (LODR) , 2015 Intimation of Loss of Share Certificate.
12-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation of information/request received from member for Loss of share certificate / Duplicate issue of Share Certificate.
11-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Prior Intimation For Fund Raising

Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/12/2023 ,inter alia, to consider and approve for fund raising upto Rs. 120 crores by way of further public offer, right issue, ADR/GDR/FCCB, QIP, Debt issue, preferential issue or any other method.
08-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window

Pursuant to SEBI (Prohibition of Insider Trading) Regulations,2015 and Code of Conduct for Prevention of Insider Trading of Fredun Pharmaceuticals Ltd the trading window for dealing in securities of the Company will remain closed for designated persons and their immediative relatives with effect from December 07,2023 till 48 hours after the end of the Board Meeting wherein the approval for raising funds would be considered approved and declared. The said information is being notified to all designated persons under the above regulations.
07-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for ALLOTMENT OF 5000 EQUITY SHARES TO NON-PROMOTER UPON CONVERSION OF WARRANTS INTO EQUITY SHARES

This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters and Non-promoters on October 15, 2022. Further, we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs. 24,90,500/- and have applied for exercising their rights for conversion of 5,000 warrants into equivalent number of Equity Shares.
05-12-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Change in Management

Appointment of Ms. Daisy D`souza (DIN: 09348309) as an Additional Independent Director of the Company for the term of 5 years wef 24th November, 2023 to 23rd November 2028.
24-11-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Dated 24.11.2023

Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we would like to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors have, vide Resolution dated 24th November, 2023, have appointed Ms. Daisy Cyril Dsouza (DIN: 09348309) as an Additional Director in the category of Independent Director of the Company for a term of five years with effect from 24th November, 2023 subject to the approval of shareholders.
24-11-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Dated November 10, 2023

This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters on October 15, 2022. Further, we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs. 50,00,000/- and have applied for exercising their rights for conversion of 10,000 warrants into equivalent number of Equity Shares
10-11-2023
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Results For Quarter And Half Year Ended 30.09.2023

Results for quarter and half year ended 30.09.2023
08-11-2023
Next Page
Close

Let's Open Free Demat Account